Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 4/20 | 0.65 |
| ▸ | HTR1D | P28221 | 3/20 | 0.65 |
| ▸ | HTR6 | P50406 | 18/20 | 0.60 |
| ▸ | HTR1A | P08908 | 3/20 | 0.60 |
| ▸ | HTR2C | P28335 | 3/20 | 0.60 |
| ▸ | HTR1F | P30939 | 3/20 | 0.60 |
| ▸ | HTR7 | P34969 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HTR1E | P28566 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | HTR3A | P46098 | 1/20 | 0.58 |
| ▸ | HTR5A | P47898 | 1/20 | 0.58 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104621 | 1.00 | HTR1B (0.65) | HTR1BHTR1DHTR6HTR1AHTR2C | |
| SCHEMBL8790532 | 0.97 | HTR1B (0.64) | HTR1BHTR1DHTR6HTR1AHTR2C | |
| SCHEMBL8790536 | 0.97 | HTR1B (0.64) | HTR1BHTR1DHTR6HTR1AHTR2C | |
| SCHEMBL8789339 | 0.91 | HTR6 (0.56) | HTR1BHTR1DHTR6HTR1AHTR2C | |
| SCHEMBL8789329 | 0.91 | HTR6 (0.56) | HTR1BHTR1DHTR6HTR1AHTR2C | |
| SCHEMBL8874424 | 0.85 | HTR6 (0.62) | HTR1BHTR1DHTR6HTR1AHTR2C | |
| SCHEMBL8874433 | 0.85 | HTR6 (0.62) | HTR1BHTR1DHTR6HTR1AHTR2C | |
| SCHEMBL8699573 | 0.83 | HTR6 (0.64) | HTR1BHTR1DHTR6HTR1AHTR2C | |
| SCHEMBL8699581 | 0.83 | HTR6 (0.64) | HTR1BHTR1DHTR6HTR1AHTR2C | |
| SCHEMBL8789718 | 0.82 | HTR6 (0.56) | HTR1BHTR1DHTR6HTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0696194-B1 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | PFIZER (US) | 2002-08-21 | — | — | EP | claimed |
| EP-0592438-B1 | INDOLE DERIVATIVES | PFIZER (US) | 1997-08-27 | — | — | EP | claimed |
| US-5618834-A | Indole derivatives in the treatment of emesis | PFIZER INC. (US) | 1997-04-08 | — | — | US | claimed |
| US-5578612-A | Indole derivatives | PFIZER INC. (US) | 1996-11-26 | — | — | US | claimed |
| EP-0714659-A2 | Indole derivatives in the treatment of emesis | Pfizer Limited (GB) | 1996-06-05 | — | — | EP | claimed |
| EP-0696194-A1 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | PFIZER INC. (US) | 1996-02-14 | — | — | EP | claimed |
| WO-1994025023-A9 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | — | 1995-10-05 | — | — | WO | claimed |
| WO-1994025023-A1 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | PFIZER INC. (US) | 1994-11-10 | — | — | WO | claimed |
| CN-1515252-A | Application of indole derivative as SHTI excitomotor | — | 2004-07-28 | — | — | CN | disclosed |
| CN-1515252-A | Application of indole derivative as SHTI excitomotor | — | 2004-07-28 | — | — | CN | disclosed |
| CN-1509713-A | Indole derivative use as 5HT1 antagonist agent | — | 2004-07-07 | — | — | CN | disclosed |
| CN-1509713-A | Indole derivative use as 5HT1 antagonist agent | — | 2004-07-07 | — | — | CN | disclosed |
| US-20030055098-A1 | Method of treatment | PFIZER INC. | 2003-03-20 | — | — | US | disclosed |
| US-6455567-B1 | TREATING DERMATOLOGICAL DISORDERS BY ADMINISTERING A 3-(PYRROLIDIN-2-YLMETHYL)-5-(AMINOSULFONYLMETHYL)INDOLE | PFIZER INC. | 2002-09-24 | — | — | US | disclosed |
| EP-0696194-A1 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | PFIZER INC. (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994025023-A9 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | — | 1995-10-05 | — | — | WO | disclosed |
| WO-1994025023-A9 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | — | 1995-10-05 | — | — | WO | disclosed |
| WO-1994025023-A1 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | PFIZER INC. (US) | 1994-11-10 | — | — | WO | disclosed |
| WO-1994025023-A1 | USE OF INDOLE DERIVATIVES AS 5HT1 ANTAGONISTS | PFIZER INC. (US) | 1994-11-10 | — | — | WO | disclosed |
| WO-1992006973-A1 | INDOLE DERIVATIVES | PFIZER INC. (US) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055098-A1 | Method of treatment | HRH2, CNR2, HRH1 | HTR1B 155/4885HTR1D 198/4885HTR6 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.